Therapeutic Area | MeSH |
---|---|
signs and symptoms pathological conditions | D013568 |
mental disorders | D001523 |
Brand Name | Status | Last Update |
---|---|---|
fluoxetine | ANDA | 2025-05-14 |
fluoxetine hcl | ANDA | 2025-01-22 |
fluoxetine hydrochloride | ANDA | 2025-05-20 |
gaboxetine | unapproved drug other | 2011-08-01 |
olanzapine and fluoxetine | ANDA | 2025-03-27 |
prozac | New Drug Application | 2024-11-13 |
sentraflox am-10 | unapproved drug other | 2011-08-17 |
sentroxatine | unapproved drug other | 2011-08-01 |
symbyax | New Drug Application | 2025-01-22 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Depression | D003863 | — | F33.9 | — | — | 1 | — | — | 1 |
Major depressive disorder | D003865 | EFO_0003761 | F22 | — | — | 1 | — | — | 1 |
Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | 1 | — | — | 1 |
Drug common name | Fluoxetine |
INN | fluoxetine |
Description | N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine is an aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group. It is a member of (trifluoromethyl)benzenes, an aromatic ether and a secondary amino compound. |
Classification | Small molecule |
Drug class | antidepressants (fluoxetine type) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1 |
PDB | — |
CAS-ID | 54910-89-3 |
RxCUI | — |
ChEMBL ID | CHEMBL41 |
ChEBI ID | 86990 |
PubChem CID | 3386 |
DrugBank | DB00472 |
UNII ID | 01K63SUP8D (ChemIDplus, GSRS) |